Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ovarian suppression plus letrozole versus ovarian suppression plus letrozole plus everolimus in premenopausal hormone receptor-positive recurrent/metastatic breast cancer
KCT0003441Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Feb 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus, letrozole, leuprolide, goserelin in breast cancer, sponsored by Asan Medical Center. Started Feb 2014; status: completed.
02
Drugs
everolimusletrozoleleuprolidegoserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0003441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003441.